These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2213 related items for PubMed ID: 20814967

  • 1. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
    Cosman F, Eriksen EF, Recknor C, Miller PD, Guañabens N, Kasperk C, Papanastasiou P, Readie A, Rao H, Gasser JA, Bucci-Rechtweg C, Boonen S.
    J Bone Miner Res; 2011 Mar; 26(3):503-11. PubMed ID: 20814967
    [Abstract] [Full Text] [Related]

  • 2. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial.
    Deal C, Omizo M, Schwartz EN, Eriksen EF, Cantor P, Wang J, Glass EV, Myers SL, Krege JH.
    J Bone Miner Res; 2005 Nov; 20(11):1905-11. PubMed ID: 16234962
    [Abstract] [Full Text] [Related]

  • 3. Intravenous Zoledronic Acid 5 mg on Bone Turnover Markers and Bone Mineral Density in East China Subjects with Newly Diagnosed Osteoporosis: A 24-month Clinical Study.
    Liang BC, Shi ZY, Wang B, Wu P, Kong LC, Yao JL, Li CW, Shi XL.
    Orthop Surg; 2017 Feb; 9(1):103-109. PubMed ID: 28276638
    [Abstract] [Full Text] [Related]

  • 4. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J.
    Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of recombinant human parathyroid hormone (1-34) are similar to those of alendronate in the treatment of postmenopausal osteoporosis.
    Deng J, Feng Z, Li Y, Pan T, Li Q, Zhao C.
    Medicine (Baltimore); 2018 Nov; 97(47):e13341. PubMed ID: 30461654
    [Abstract] [Full Text] [Related]

  • 6. Comparative efficacy of bone anabolic therapies in women with postmenopausal osteoporosis: A systematic review and network meta-analysis of randomized controlled trials.
    Hernandez AV, Pérez-López FR, Piscoya A, Pasupuleti V, Roman YM, Thota P, Herrera A.
    Maturitas; 2019 Nov; 129():12-22. PubMed ID: 31547908
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial.
    Leder BZ, Tsai JN, Uihlein AV, Burnett-Bowie SA, Zhu Y, Foley K, Lee H, Neer RM.
    J Clin Endocrinol Metab; 2014 May; 99(5):1694-700. PubMed ID: 24517156
    [Abstract] [Full Text] [Related]

  • 9. Bone turnover markers to explain changes in lumbar spine BMD with abaloparatide and teriparatide: results from ACTIVE.
    Eastell R, Mitlak BH, Wang Y, Hu M, Fitzpatrick LA, Black DM.
    Osteoporos Int; 2019 Mar; 30(3):667-673. PubMed ID: 30635696
    [Abstract] [Full Text] [Related]

  • 10. Effect of teriparatide [rhPTH(1-34)] on BMD when given to postmenopausal women receiving hormone replacement therapy.
    Ste-Marie LG, Schwartz SL, Hossain A, Desaiah D, Gaich GA.
    J Bone Miner Res; 2006 Feb; 21(2):283-91. PubMed ID: 16418784
    [Abstract] [Full Text] [Related]

  • 11. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT).
    Black DM, Reid IR, Boonen S, Bucci-Rechtweg C, Cauley JA, Cosman F, Cummings SR, Hue TF, Lippuner K, Lakatos P, Leung PC, Man Z, Martinez RL, Tan M, Ruzycky ME, Su G, Eastell R.
    J Bone Miner Res; 2012 Feb; 27(2):243-54. PubMed ID: 22161728
    [Abstract] [Full Text] [Related]

  • 12. Effects of morning vs. evening teriparatide injection on bone mineral density and bone turnover markers in postmenopausal osteoporosis.
    Michalska D, Luchavova M, Zikan V, Raska I, Kubena AA, Stepan JJ.
    Osteoporos Int; 2012 Dec; 23(12):2885-91. PubMed ID: 22426952
    [Abstract] [Full Text] [Related]

  • 13. Usefulness of daily teriparatide treatment in elderly patients over 80 years of age.
    Niimi R, Kono T, Nishihara A, Hasegawa M, Matsumine A, Kono T, Sudo A.
    Osteoporos Int; 2016 May; 27(5):1869-74. PubMed ID: 26759334
    [Abstract] [Full Text] [Related]

  • 14. Analysis of daily teriparatide treatment for osteoporosis in men.
    Niimi R, Kono T, Nishihara A, Hasegawa M, Matsumine A, Kono T, Sudo A.
    Osteoporos Int; 2015 Apr; 26(4):1303-9. PubMed ID: 25567777
    [Abstract] [Full Text] [Related]

  • 15. Effect of teriparatide on bone mineral density and biochemical markers in Japanese women with postmenopausal osteoporosis: a 6-month dose-response study.
    Miyauchi A, Matsumoto T, Shigeta H, Tsujimoto M, Thiebaud D, Nakamura T.
    J Bone Miner Metab; 2008 Apr; 26(6):624-34. PubMed ID: 18979163
    [Abstract] [Full Text] [Related]

  • 16. Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized controlled trial.
    McClung M, Miller P, Recknor C, Mesenbrink P, Bucci-Rechtweg C, Benhamou CL.
    Obstet Gynecol; 2009 Nov; 114(5):999-1007. PubMed ID: 20168099
    [Abstract] [Full Text] [Related]

  • 17. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial.
    Saag KG, Zanchetta JR, Devogelaer JP, Adler RA, Eastell R, See K, Krege JH, Krohn K, Warner MR.
    Arthritis Rheum; 2009 Nov; 60(11):3346-55. PubMed ID: 19877063
    [Abstract] [Full Text] [Related]

  • 18. Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment.
    Miller PD, Schwartz EN, Chen P, Misurski DA, Krege JH.
    Osteoporos Int; 2007 Jan; 18(1):59-68. PubMed ID: 17013567
    [Abstract] [Full Text] [Related]

  • 19. Effect of Teriparatide Treatment on Circulating Periostin and Its Relationship to Regulators of Bone Formation and BMD in Postmenopausal Women With Osteoporosis.
    Gossiel F, Scott JR, Paggiosi MA, Naylor KE, McCloskey EV, Peel NFA, Walsh JS, Eastell R.
    J Clin Endocrinol Metab; 2018 Apr 01; 103(4):1302-1309. PubMed ID: 29365099
    [Abstract] [Full Text] [Related]

  • 20. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
    Gallagher JC, Rosen CJ, Chen P, Misurski DA, Marcus R.
    Bone; 2006 Dec 01; 39(6):1268-75. PubMed ID: 16884968
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 111.